Literature DB >> 8707287

Cellular distribution of transcripts for tissue inhibitor of metalloproteinases 1 and 2 in human hepatocellular carcinomas.

H Nakatsukasa1, K Ashida, T Higashi, S Ohguchi, S Tsuboi, N Hino, K Nouso, Y Urabe, N Kinugasa, K Yoshida, S Uematsu, M Ishizaki, Y Kobayashi, T Tsuji.   

Abstract

The cellular distribution of tissue inhibitor of metalloproteinases (TIMP)-1, and TIMP-2 was studied by using in situ hybridization in surgically removed human hepatocellular carcinomas (HCCs) and cholangiocellular carcinomas (CCCs). The purpose of this study was to characterize the protein involvement of TIMPs in the development of HCCs and CCCs. All HCCs and CCCs expressed TIMPs. The distribution of transcripts for TIMPs in the tumors was mostly homogeneous. Expression of TIMP in cancer cells was more intense than that in the surrounding noncancerous liver (either, cirrhosis, chronic hepatitis, or normal), and expression of TIMP-1 was stronger than that of TIMP-2. Expression of TIMPs varied among HCC nodules, but there was no obvious association between the expression level of TIMPs and differentiation stages or invasiveness of the HCCs. Transcripts for TIMPs were clearly demonstrated in the metastatic HCC nodules in the lung. Expression of TIMP-1 CCC was strong, and small nodules of CCC were recognized in the liver. Immunohistochemical study for TIMP-1 revealed a consistent staining of the TIMP protein with the transcripts. In the peritumoral histologically normal liver, which was not infected with either hepatitis B or C virus, expression of TIMP-1 was found in various cell types, but that of TIMP-2 was weak. Expression of TIMP-1 in hepatocytes revealed clear zonal distribution. These results suggest that TIMPs may act on modulating the matrix/tumor interaction and may play an important role in growth and invasion of HCCs and CCCs. Expression of TIMP-1 can be a marker of HCC metastasis to the lung, and also that of the extent of CCC invasion. Furthermore, the consistent expression of TIMPs in many cell types of the noncancerous liver suggests some unknown functional role that must be clarified.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8707287     DOI: 10.1053/jhep.1996.v24.pm0008707287

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  14 in total

1.  Self-regulation of type I collagen degradation by collagen-induced production of matrix metalloproteinase-1 on cholangiocarcinoma and hepatocellular carcinoma cells.

Authors:  M Enjoji; K Kotoh; H Iwamoto; M Nakamuta; H Nawata
Journal:  In Vitro Cell Dev Biol Anim       Date:  2000-02       Impact factor: 2.416

2.  Enhanced migration of tissue inhibitor of metalloproteinase overexpressing hepatoma cells is attributed to gelatinases: relevance to intracellular signaling pathways.

Authors:  Elke Roeb; Anja-Katrin Bosserhoff; Sabine Hamacher; Bettina Jansen; Judith Dahmen; Sandra Wagner; Siegfried Matern
Journal:  World J Gastroenterol       Date:  2005-02-28       Impact factor: 5.742

3.  Suppression of hepatic tumor growth and metastasis by metronomic therapy in a rat model of hepatocellular carcinoma.

Authors:  Jeong Won Jang; Seong Tae Park; Jung Hyun Kwon; Chan Ran You; Jong Young Choi; Chan Kwon Jung; Si Hyun Bae; Seung Kew Yoon
Journal:  Exp Mol Med       Date:  2011-05-31       Impact factor: 8.718

4.  Differential expression and origin of membrane-type 1 and 2 matrix metalloproteinases (MT-MMPs) in association with MMP2 activation in injured human livers.

Authors:  N Théret; O Musso; A L'Helgoualc'h; J P Campion; B Clément
Journal:  Am J Pathol       Date:  1998-09       Impact factor: 4.307

5.  Overexpression of tissue inhibitor of matrix metalloproteinases-1 (TIMP-1) in metastatic MDCK cells transformed by v-src.

Authors:  H Noritake; H Miyamori; C Goto; M Seiki; H Sato
Journal:  Clin Exp Metastasis       Date:  1999-03       Impact factor: 5.150

6.  The Contribution of Matrix Metalloproteinase-1 Genotypes to Hepatocellular Carcinoma Susceptibility in Taiwan.

Authors:  Yi-Liang Lai; Chi-Li Gong; Chun-Kai Fu; Te-Cheng Yueh; Chia-Wen Tsai; Wen-Shin Chang; Chieh-Lun Hsiao; Shiou-Ting Yen; Hsin-Ting Li; Long-Bin Jeng; Shou-Cheng Wang; DA-Tian Bau
Journal:  Cancer Genomics Proteomics       Date:  2017 Mar-Apr       Impact factor: 4.069

7.  Cellular distribution of 92-kd type IV collagenase/gelatinase B in human hepatocellular carcinoma.

Authors:  K Ashida; H Nakatsukasa; T Higashi; S Ohguchi; N Hino; K Nouso; Y Urabe; K Yoshida; N Kinugasa; T Tsuji
Journal:  Am J Pathol       Date:  1996-12       Impact factor: 4.307

8.  Evidence for altered hepatic matrix degradation in genetic haemochromatosis.

Authors:  D K George; G A Ramm; L W Powell; L M Fletcher; N I Walker; L L Cowley; D H Crawford
Journal:  Gut       Date:  1998-05       Impact factor: 23.059

9.  Elevated levels of tissue inhibitor of metalloproteinases (TIMPS) in human hepatocellular carcinomas.

Authors:  Eiji Matsumoto; Harushige Nakatsukasa; Kazuhiro Nouso; Shin-Ichiro Nakamura; Mayumi Suzuki; Yoshiyuki Kobayashi; Masayuki Uemura; Syuichiro Sato; Ei-Ichiro Yumoto; Junko Yokoyama; Sou Tsuboi; Hironori Tanaka; Yoshiataka Takuma; Tatsuya Fujikawa; Yasushi Shiratori
Journal:  Comp Hepatol       Date:  2004-01-14

10.  11-epi-Sinulariolide acetate reduces cell migration and invasion of human hepatocellular carcinoma by reducing the activation of ERK1/2, p38MAPK and FAK/PI3K/AKT/mTOR signaling pathways.

Authors:  Jen-Jie Lin; Jui-Hsin Su; Chi-Chu Tsai; Yi-Jen Chen; Ming-Hui Liao; Yu-Jen Wu
Journal:  Mar Drugs       Date:  2014-09-12       Impact factor: 5.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.